

Orgovyx (relugolix)
Effective 07/01/2021

Plan	<input type="checkbox"/> MassHealth UPPL <input checked="" type="checkbox"/> Commercial/Exchange	Program Type	<input checked="" type="checkbox"/> Prior Authorization <input checked="" type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Benefit	<input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit (NLX)		
Specialty Limitations	This medication has been designated specialty and must be filled at a contracted specialty pharmacy.		
Contact Information	Specialty Medications		
	All Plans	Phone: 866-814-5506	Fax: 866-249-6155
	Non-Specialty Medications		
	MassHealth	Phone: 877-433-7643	Fax: 866-255-7569
	Commercial	Phone: 800-294-5979	Fax: 888-836-0730
	Exchange	Phone: 855-582-2022	Fax: 855-245-2134
	Medical Specialty Medications (NLX)		
	All Plans	Phone: 844-345-2803	Fax: 844-851-0882
Exceptions	N/A		

Overview

Orgovyx (relugolix) is a nonpeptide GnRH receptor antagonist that competitively binds to pituitary GnRH receptors, thereby reducing the release of luteinizing hormone and follicle-stimulating hormone, and consequently testosterone, for the treatment of adult patients with advanced prostate cancer.

Coverage Guidelines

Authorization may be granted for members new to the plan who are currently receiving treatment with Orgovyx, excluding when the product is obtained as samples or via manufacturer's patient assistance programs.

OR

Authorization may be granted for members when ALL the following criteria are met, and documentation is provided:

1. Member has a diagnosis of advanced prostate cancer
2. The member is \geq 18 years old

Continuation of Therapy

Reauthorization may be granted for members when provider documents positive response to therapy.

Limitations

1. Initial approvals and reauthorizations will be for 12 months.
2. The following quantity limits apply:

Orgovyx 120mg capsules	30 capsules per 28 days
------------------------	-------------------------

References

1. Orgovyx [package insert]. Brisbane, CA: Myovant Sciences, Inc; December 2020.

Review History

05/19/2021 – Created and Reviewed at May P&T. Effective 07/01/2021.

